Israel’s 2019 Genesis Prize winner, Natan Sharansky, donated his $1 million prize to 10 Israeli startups developing innovations to combat Covid-19. The 10 are Kamada, Pluristem, Sight Diagnostics, Sonovia, Biobeat, EyeControl, K Health, Picodya, IAI and MyZeppi. https://nocamels.com/2020/12/sharansky-genesis-prize-10-companies-covid/ https://www.genesisprize.org/press-center/2020-12-24-genesis-prize-and-start-up-nation-central-announce-winners-of-the-competition-in-honor-of-natan-sharansky

Israel’s Pluristem (reported here previously) and the Abu Dhabi Stem Cells Center (ADSCC) have unveiled their first joint projects. One – a potential Covid-19 treatment – is the first time Pluristem’s PLX cells will have been administered via a nebulizer. … Continue reading →

Israel’s Pluristem (reported here previously) has launched an FDA-cleared Covid-19 expanded access program. It enables Pluristem to use its PLX-PAD cells to treat up to 100 more infected patients outside its current trials in the USA and Europe and compassionate … Continue reading →

Six critically ill Israeli coronavirus patients with organ failure are still alive after 1-week’s Pluristem’s PLX cell-therapy in three separate Israeli medical centers. Four show improved respiratory parameters – three of those could soon be weaned off ventilators with two … Continue reading →

As reported in the 22nd Mar newsletter, Israel’s Pluristem is developing a treatment for severe coronavirus patients.  Latest news is that Pluristem has begun human testing in Israel. https://www.jpost.com/health-science/israels-company-uses-placenta-cells-to-treat-critical-covid-19-patients-622960

Israel’s Pluristem Therapeutics’s placenta-based cell therapy (see here) could be used to treat patients suffering from respiratory and inflammatory complications associated with coronavirus. Pluristem has launched a joint project with two Berlin-based medical institutions. https://www.jpost.com/HEALTH-SCIENCE/Israeli-cell-therapy-to-treat-acute-COVID-19-patients-prevent-ARDS-621016 https://unitedwithisrael.org/novel-israeli-therapy-takes-aim-at-coronavirus/

I reported previously (see here) on the PLX-R18 stem cell treatment for radiation sickness from Israel’s Pluristem. Animal trials by the US Department of Defense demonstrated that PLX-R18, administered before and after radiation exposure increased survival rates by 46-70%. https://www.jpost.com/HEALTH-SCIENCE/Pluristem-gets-positive-results-from-radiation-treatment-trials-597271